Drugs /

repotrectinib

Back to Drugs List

Overview

Generic Name(s):
repotrectinib
NCI Definition [1]:
An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.

Clinical Trials

View Clinical Trials for repotrectinib

Repotrectinib has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating repotrectinib, 2 are phase 1/phase 2 (2 open).

ALK Fusion, NTRK1 Fusion, and NTRK2 Fusion are the most frequent biomarker inclusion criteria for repotrectinib clinical trials.

Malignant solid tumor and anaplastic large cell lymphoma are the most common diseases being investigated in repotrectinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Repotrectinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating repotrectinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
alk/ros1/ntrk/src/fak multikinase inhibitor tpx-0005, tpx-0005, multikinase inhibitor tpx-0005, multi-kinase inhibitor tpx-0005
Drug Target(s) [2]:
ALK, JAK2, NTRK1, NTRK2, NTRK3, PTK2, ROS1, SRC
NCIT ID [1]:
C133821

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.